Aprea Therapeutics, Inc. (APRE) - Dilution Analysis

10-Q filing | 12.4M shares outstanding

8-K filing: Aprea Therapeutics, Inc. entered into a securities purchase agreement with accredited investors to issue and sell pre-funded Common Stock purchase warrants and common stock purchase warrants, expecting gross proceeds of approximately $30 million. ($30.0M proceeds)

10-K filing | 8.2M shares outstanding

8-K filing: Aprea Therapeutics, Inc. entered into a securities purchase agreement to issue and sell 6,288,857 shares of common stock or pre-funded warrants and common stock purchase warrants to purchase up to 6,288,857 shares of common stock at a combined effective offering price of $0.89 per share for gross proceeds of approximately $5.6 million, expected to close on January 30, 2026. ($5.6M proceeds)

S-3 filing: This prospectus relates to the possible resale of 5,503,556 shares of common stock by selling stockholders.

8-K filing: Aprea Therapeutics, Inc. entered into a securities purchase agreement with accredited investors and Company insiders to issue and sell 2,623,023 shares of common stock or pre-funded warrants, and common stock purchase warrants to purchase up to 2,623,023 shares of common stock, for expected aggregate gross proceeds of approximately $3.1 million. ($3.1M proceeds)

10-Q filing | 6.4M shares outstanding

10-Q filing | 6.1M shares outstanding

10-Q filing | 6.0M shares outstanding

10-K filing | 5.5M shares outstanding

10-Q filing | 5.9M shares outstanding

10-Q filing | 5.9M shares outstanding

10-Q filing | 5.4M shares outstanding

S-3 filing: This is an S-3 filing for the resale of 4,389,576 shares of common stock by selling stockholders.

10-K filing | 3.6M shares outstanding

8-K filing: Aprea Therapeutics entered into a securities purchase agreement to issue and sell common stock, pre-funded warrants, and common stock purchase warrants for gross proceeds of approximately $16.0 million and potential future warrant cash exercise gross proceeds of approximately $18.0 million. ($12.3M proceeds)

S-3 filing: APREA THERAPEUTICS, INC. is offering common stock, preferred stock, warrants, debt securities, rights to purchase common stock, preferred stock, debt securities or units, as well as units that include any of these securities, with an aggregate offering price of up to $150,000,000. A separate at-the-market offering will be made for up to $1,000,000 of common stock through Wainwright.

10-Q filing | 3.7M shares outstanding

10-Q filing | 3.7M shares outstanding

10-Q filing | 3.7M shares outstanding

10-K filing | 2.7M shares outstanding

8-K filing: Aprea Therapeutics, Inc. entered into an underwriting agreement to issue and sell 1,050,000 shares of common stock at $5.25 per share, with an option for the underwriters to purchase an additional 157,500 shares. ($4.8M proceeds)

8-K filing: Stock split 1-for-20 | Outstanding: 52,237,885 → 2,611,894

10-Q filing | 52.2M shares outstanding

10-Q filing | 22.7M shares outstanding

8-K filing: Aprea Therapeutics acquired Atrin Pharmaceuticals in a merger, issuing 1,117,394 shares of common stock and 2,949,630 shares of Series A Preferred Stock to Atrin's securityholders. Aprea intends to hold a vote to approve a reverse stock split.

10-Q filing | 21.9M shares outstanding

10-K filing | 21.3M shares outstanding

10-Q filing | 21.2M shares outstanding

10-Q filing | 21.2M shares outstanding

10-Q filing | 21.2M shares outstanding

10-K filing | 21.2M shares outstanding

S-3/A filing: Aprea Therapeutics may offer and sell shares of common stock, shares of preferred stock, debt securities, warrants, rights to purchase common stock, preferred stock, debt securities or units, as well as units that include any of these securities for up to $350,000,000.

S-3 filing: Aprea Therapeutics files an S-3 form to register the offer and sale of common stock, preferred stock, debt securities, warrants, rights to purchase common stock, preferred stock, debt securities or units, as well as units that include any of these securities, with an aggregate offering price of up to $350,000,000.

10-Q filing | 21.2M shares outstanding

10-Q filing | 21.2M shares outstanding

10-Q filing | 21.1M shares outstanding

10-K filing | 21.1M shares outstanding